2nd Quarter - Amendment — AVANIR PHARMACEUTICALS for AVANIR PHARMACEUTICALS (2016)

Firm

AVANIR PHARMACEUTICALS

Client

AVANIR PHARMACEUTICALS

Income

—

Expenses

$110,000

Expense method

A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
2nd Quarter - Report	Jul 19, 2016	$110,000	Replaced
2nd Quarter - Amendment (this page)	Jul 19, 2016	$110,000	Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Drug pricing

Lobbyist	Covered position, as disclosed
CRYSTAL LYNN VANUCH	—

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); Food & Drug Administration (FDA); SENATE

Health Issues HCR

21st Century Cures, Specialty Tier Price Cap Legislation, Health Care Quality Measures

Lobbyist	Covered position, as disclosed
CRYSTAL LYNN VANUCH	Head of Government Affairs

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS); SENATE

Budget/Appropriations BUD

Brain injury funding in the FY17 Labor, HHS, Education Appropriations Bills

Lobbyist	Covered position, as disclosed
CRYSTAL LYNN VANUCH	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.